Two trials presented at the Society of Gynecologic Oncology have shown significant improvement in progression free survival for patients with advanced endometrial cancer and mismatch repair deficient disease. In the first trial, 816 patients with measurable stage III or IVA disease, stage IVB diseaes, or recurrent disease received first-line carboplatin and paclitaxel with or without pembrolizumab. Among those who had dMMR, the addition of pembro nearly double the rate of PFS at 12 months from 38% to 74% and prolonged median PFS from 8.7 to 13.1 months. In the second trial, 494 patients with advanced stage III, stage IV, or recurrent endometrial cancer received first line carboplatin and paclitaxel with or without dostarlimab. Among those with dMMR (23.9%), the addition of dostarlimab quadrupled the rate of PFS at 24 months from 15.7% to 61.4%. | Mirza, N Engl J Med 2023 & Eskander, N Engl J Med 2023
